Inhibitory Effects of Amiodarone and Its N-deethylated Metabolite on Human Cytochrome P450 Activities: Prediction of in Vivo Drug Interactions

Overview

Journal Br J Clin Pharmacol

Specialty Pharmacology

Date 2000 Mar 16

PMID 10718780

Citations 50

Authors

K Ohyama

M Nakajima

M Suzuki

N Shimada

H Yamazaki

T Yokoi

Affiliations

Soon will be listed here.

Abstract

Aims: To predict the drug interactions of amiodarone and other drugs, the inhibitory effects and inactivation potential for human cytochrome P450 (CYP) enzymes by amiodarone and its N-dealkylated metabolite, desethylamiodarone were examined.

Methods: The inhibition or inactivation potency of amiodarone and desethylamiodarone for human CYP activities were investigated using microsomes from B-lymphoblastoid cell lines expressing CYP1A1, CYP1A2, CYP2A6, CYP2B6, CYP2C9, CYP2C19, CYP2D6, CYP2E1, and CYP3A4. The in vivo drug interactions of amiodarone and desethylamiodarone were predicted in vitro using the 1+Iu/Ki values.

Results: Amiodarone weakly inhibited CYP2C9, CYP2D6, and CYP3A4-mediated activities with Ki values of 45.1-271.6 microm. Desethylamiodarone competitively inhibited the catalytic activities of CYP2D6 (Ki=4.5 microm ) and noncompetitively inhibited CYP2A6 (Ki=13.5 microm ), CYP2B6 (Ki=5.4 microm ), and CYP3A4 (Ki=12.1 microm ). The catalytic activities of CYP1A1 (Ki=1.5 microm, alpha=5.7), CYP1A2 (Ki=18.8 microm, alpha=2.6), CYP2C9 (Ki=2.3 microm, alpha=5.9), and CYP2C19 (Ki=15.7 microm, alpha=4.5) were inhibited by desethylamiodarone with mixed type. The 1+Iu/Ki values of desethylamiodarone were higher than those of amiodarone. Amiodarone inactivated CYP3A4, while desethylamiodarone inactivated CYP1A1, CYP1A2, CYP2B6, and CYP2D6.

Conclusions: The interactions between amiodarone and other drugs might occur via the inhibition of CYP activities by its N-dealkylated metabolite, desethylamiodarone, rather than by amiodarone itself. In addition, the inactivation of CYPs by desethylamiodarone as well as by amiodarone would also contribute to the drug interactions.

Citing Articles

Effect of CYP2D6, 2C19, and 3A4 Phenoconversion in Drug-Related Deaths.

Aly S, Hennart B, Gaulier J, Allorge D Toxics. 2024; 12(4).

PMID: 38668482 PMC: 11054314. DOI: 10.3390/toxics12040260.

Impact of amiodarone use on metoprolol concentrations, α-OH-metoprolol concentrations, metoprolol dosing and heart rate: A cross-sectional study.

Robert S, Pilon M, Oussaid E, Meloche M, Leclair G, Jutras M Pharmacol Res Perspect. 2023; 11(5):e01137.

PMID: 37732835 PMC: 10512912. DOI: 10.1002/prp2.1137.

Desipramine induces eryptosis in human erythrocytes, an effect blunted by nitric oxide donor sodium nitroprusside and N-acetyl-L-cysteine but enhanced by Calcium depletion.

Pan X, Giustarini D, Lang F, Rossi R, Wieder T, Koberle M Cell Cycle. 2023; 22(17):1827-1853.

PMID: 37522842 PMC: 10599211. DOI: 10.1080/15384101.2023.2234177.

Strategies for Avoiding Typical Drug-Drug Interactions and Drug-Related Problems in Patients with Vascular Diseases.

Schmelzer K, Liebetrau D, Kammerer W, Meisinger C, Hyhlik-Durr A Medicina (Kaunas). 2023; 59(4).

PMID: 37109738 PMC: 10142821. DOI: 10.3390/medicina59040780.

Administration of Secretome Derived from Human Mesenchymal Stem Cells Induces Hepatoprotective Effects in Models of Idiosyncratic Drug-Induced Liver Injury Caused by Amiodarone or Tamoxifen.

Huang Y, De Gregorio C, Silva V, Elorza A, Leniz P, Aliaga-Tobar V Cells. 2023; 12(4).

PMID: 36831304 PMC: 9954258. DOI: 10.3390/cells12040636.

References

Staubli M, BIRCHER J, Galeazzi R, REMUND H, STUDER H . Serum concentrations of amiodarone during long term therapy. Relation to dose, efficacy and toxicity. Eur J Clin Pharmacol. 1983; 24(4):485-94. DOI: 10.1007/BF00609891. View

Chitwood K . Cyclosporine-amiodarone interaction. Ann Pharmacother. 1993; 27(5):569-71. DOI: 10.1177/106002809302700506. View

Heger J, Prystowsky E, Zipes D . Relationships between amiodarone dosage, drug concentrations, and adverse side effects. Am Heart J. 1983; 106(4 Pt 2):931-5. DOI: 10.1016/0002-8703(83)90018-2. View

Kunze K, TRAGER W . Isoform-selective mechanism-based inhibition of human cytochrome P450 1A2 by furafylline. Chem Res Toxicol. 1993; 6(5):649-56. DOI: 10.1021/tx00035a009. View

Fabre G, Julian B, Saint-Aubert B, Joyeux H, Berger Y . Evidence for CYP3A-mediated N-deethylation of amiodarone in human liver microsomal fractions. Drug Metab Dispos. 1993; 21(6):978-85. View

Funck-Brentano C, Becquemont L, Kroemer H, Buhl K, Knebel N, Eichelbaum M . Variable disposition kinetics and electrocardiographic effects of flecainide during repeated dosing in humans: contribution of genetic factors, dose-dependent clearance, and interaction with amiodarone. Clin Pharmacol Ther. 1994; 55(3):256-69. DOI: 10.1038/clpt.1994.26. View

Jaruratanasirikul S, Hortiwakul R . The inhibitory effect of amiodarone and desethylamiodarone on dextromethorphan O-demethylation in human and rat liver microsomes. J Pharm Pharmacol. 1994; 46(11):933-5. DOI: 10.1111/j.2042-7158.1994.tb05721.x. View

Chiba M, Nishime J, Lin J . Potent and selective inactivation of human liver microsomal cytochrome P-450 isoforms by L-754,394, an investigational human immune deficiency virus protease inhibitor. J Pharmacol Exp Ther. 1995; 275(3):1527-34. View

Lang D, Bocker R . Highly sensitive and specific high-performance liquid chromatographic analysis of 7-hydroxywarfarin, a marker for human cytochrome P-4502C9 activity. J Chromatogr B Biomed Appl. 1995; 672(2):305-9. DOI: 10.1016/0378-4347(95)00222-5. View

10.

Nelson D, Koymans L, Kamataki T, Stegeman J, Feyereisen R, Waxman D . P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclature. Pharmacogenetics. 1996; 6(1):1-42. DOI: 10.1097/00008571-199602000-00002. View

11.

Walker D, Alabaster C, Congrave G, Hargreaves M, Hyland R, Jones B . Significance of metabolism in the disposition and action of the antidysrhythmic drug, dofetilide. In vitro studies and correlation with in vivo data. Drug Metab Dispos. 1996; 24(4):447-55. View

12.

Court M, von Moltke L, Shader R, Greenblatt D . Biotransformation of chlorzoxazone by hepatic microsomes from humans and ten other mammalian species. Biopharm Drug Dispos. 1997; 18(3):213-26. DOI: 10.1002/(sici)1099-081x(199704)18:3<213::aid-bdd15>3.0.co;2-0. View

13.

Scheinman M . Adverse effects of amiodarone. Pacing Clin Electrophysiol. 1998; 21(1 Pt 1):108-20. DOI: 10.1111/j.1540-8159.1998.tb01068.x. View

14.

Nakajima M, Inoue T, Shimada N, Tokudome S, Yamamoto T, Kuroiwa Y . Cytochrome P450 2C9 catalyzes indomethacin O-demethylation in human liver microsomes. Drug Metab Dispos. 1998; 26(3):261-6. View

15.

He K, Iyer K, Hayes R, Sinz M, Woolf T, Hollenberg P . Inactivation of cytochrome P450 3A4 by bergamottin, a component of grapefruit juice. Chem Res Toxicol. 1998; 11(4):252-9. DOI: 10.1021/tx970192k. View

16.

Kobayashi K, Nakajima M, Chiba K, Yamamoto T, Tani M, Ishizaki T . Inhibitory effects of antiarrhythmic drugs on phenacetin O-deethylation catalysed by human CYP1A2. Br J Clin Pharmacol. 1998; 45(4):361-8. PMC: 1873964. DOI: 10.1046/j.1365-2125.1998.t01-1-00692.x. View

17.

Khojasteh-Bakht S, Koenigs L, Peter R, TRAGER W, Nelson S . (R)-(+)-Menthofuran is a potent, mechanism-based inactivator of human liver cytochrome P450 2A6. Drug Metab Dispos. 1998; 26(7):701-4. View

18.

Nakajima M, Kobayashi K, Shimada N, Tokudome S, Yamamoto T, Kuroiwa Y . Involvement of CYP1A2 in mexiletine metabolism. Br J Clin Pharmacol. 1998; 46(1):55-62. PMC: 1873982. DOI: 10.1046/j.1365-2125.1998.00048.x. View

19.

Ito K, Iwatsubo T, Kanamitsu S, Ueda K, Suzuki H, Sugiyama Y . Prediction of pharmacokinetic alterations caused by drug-drug interactions: metabolic interaction in the liver. Pharmacol Rev. 1998; 50(3):387-412. View

20.

Smith G, Stubbins M, Harries L, Wolf C . Molecular genetics of the human cytochrome P450 monooxygenase superfamily. Xenobiotica. 1999; 28(12):1129-65. DOI: 10.1080/004982598238868. View